| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Apimeds Pharmaceuticals US, Inc.
13D/A
Amendment 4
APUS · 03771D102
|
34.3% |
5/7/2026
Event 5/7/2026
|
|||
| Inscobee Inc. | 16.7% | ||||
| Apimeds Inc. | 34.3% | ||||
|
Apimeds Pharmaceuticals US, Inc.
13D/A
Amendment 3
APUS · 03771D102
|
34.3% |
3/30/2026
Event 3/25/2026
|
|||
| Inscobee Inc. | 16.7% | ||||
| Apimeds Inc. | 34.3% | ||||
|
Apimeds Pharmaceuticals US, Inc.
13D/A
Amendment 2
APUS · 03771D102
|
34.3% |
3/20/2026
Event 3/20/2026
|
|||
| Inscobee Inc. | 16.7% | ||||
| Apimeds Inc. | 34.3% | ||||
|
Apimeds Pharmaceuticals US, Inc.
13D/A
Amendment 1
APUS · 03771D102
|
34.3% |
1/26/2026
Event 12/1/2025
|
|||
| Inscobee Inc. | 16.7% | ||||
| Apimeds Inc. | 34.3% | ||||
|
Apimeds Pharmaceuticals US, Inc.
13D
APUS · 03771D102
|
37.9% |
5/19/2025
Event 5/12/2025
|
|||
| Inscobee Inc. | 17.5% | ||||
| Apimeds Inc. | 37.9% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.